Johnson & Johnson (JNJ)
DCLA's Sarat Sethi on his top stock picks: JNJ, WDAY, TMO
Sarat Sethi, DCLA managing partner, joins 'Squawk Box' to discuss the latest market trends, his top stock picks, and more.
You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth
A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend yield, trading at a forward P/E of 13.5, with potential for profitability expansion despite near-term Amazon volume reductions. Johnson & Johnson, with a 3.3% dividend yield and a forward P/E of 14.4, carries a robust pipeline and 62 years of consecutive dividend growth.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson (JNJ -0.47%) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy.
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson (JNJ -0.47%) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is growth.
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Johnson & Johnson (JNJ -0.47%) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.
US government could seek over $1 billion from J&J for cancer treatment costs
The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal health agencies' payments of medical costs for patients who allege that the company's baby powder and other talc products caused them to develop cancer, a government attorney said Friday.
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023. Moreover, Johnson & Johnson expects its operational sales to grow by 2% to 3% in 2025, while its adjusted diluted EPS will be between $10.50 and $10.70, implying single-digit percentage growth.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
The new trading year is getting started, and investors might be looking to make this one either as strong as 2024 was or even stronger yet. To do this, it is always preferred to start on a strong note, meaning that the first quarter of the year has to bring about a net outperformance to give portfolios enough momentum and room to pursue some of the more aggressive growth projects later in the year.
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferies believe. Fourth quarter Spravato sales grew by 5% quarter-over-quarter to $297 million driven by increased physician and patient demand.
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
